Thomas Flaten analyst LAKE STREET

Currently out of the existing stock ratings of Thomas Flaten, 70 are a BUY (95.89%), 3 are a HOLD (4.11%).

Thomas Flaten

Work Performance Price Targets & Ratings Chart

Analyst Thomas Flaten, currently employed at LAKE STREET, carries an average stock price target met ratio of 39.89% that have a potential upside of 47.97% achieved within 116 days.

Thomas Flaten’s has documented 139 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AQST, Aquestive Therapeutics at 07-Mar-2024.

Wall Street Analyst Thomas Flaten

Analyst best performing recommendations are on ENSC (ENSYSCE BIOSCIENCES).
The best stock recommendation documented was for ENSC (ENSYSCE BIOSCIENCES) at 12/1/2021. The price target of $960 was fulfilled within 8 days with a profit of $607.2 (172.11%) receiving and performance score of 215.14.

Average potential price target upside

ACHV Achieve Life Sciences BBI Brickell Biotech CTIC CTi Biopharma Corp DMAC DiaMedica Therapeutics DMTK DermTech VCYT Veracyte CSTL Castle Biosciences AQST Aquestive Therapeutics OCX OncoCyte Corp BFRA Biofrontera AG CKPT Checkpoint Therapeutics TCRT Alaunos Therapeutics BLFS BioLife Solutions ENSC Ensysce Biosciences EVAX Evaxion Biotech AS ZIOP ZIOPHARM Oncology ASRT Assertio Therapeutics BTTX Better Therapeutics

Analyst name


Current price target

Potential Upside

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$6.17 (127.74%)


2 months 1 days ago

0/5 (0%)

$6.19 (128.69%)


7 months 2 days ago

1/1 (100%)

$-45.93 (-79.19%)




$14.17 (293.37%)


1 years 1 months 13 days ago

0/3 (0%)

$12.8 (206.45%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Thomas Flaten is most bullish on?

Potential upside of $5.33 has been obtained for AQST (AQUESTIVE THERAPEUTICS)

What Year was the first public recommendation made by Thomas Flaten?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?